Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G for Amylyx Pharmaceuticals, Inc. Common Stock (AMLX).
- Disclosed ownership: 5.5%.
- Date of event: 30 Jun 2025.
BlackRock, Inc. - 30 Jun 2025 SCHEDULE 13G Report for Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- AMLX
- Shares outstanding
- 89,409,109 shares
- Disclosed Ownership
- 4,917,501 shares
- Ownership
- 5.5%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Jul 2025, 19:44:53 UTC
- Date of event
- 30 Jun 2025
- Next filing
- 21 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 5.5% ownership in Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Jul 2025, 19:44.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.5% | 4,917,501 | 4,827,647 | 0 | Spencer Fleming | Managing Director |